Designed to be different

STRAVIX PL Lyopreserved Umbilical Tissue and STRAVIX Cryopreserved Umbilical Tissue are highly versatile, with both wound and surgical applications:

  • Shown to improve the closure rates of challenging wounds as a cover,3 including those with exposed structures or hardware
  • Suitable as a cover for tendon, ligament, bone, nerve repair or soft tissue sites across a wide range of surgical procedures from head to toe, particularly those involving high-risk patients
  • Provide a barrier under incisions

Manufactured using proprietary lyopreservation or cryopreservation processes, blood vessels are removed to prevent an immune response while retaining growth factors and an extracellular matrix rich in hyaluronic acid.1,2

STRAVIX-HERO-2-840x840-PX.png

Product Features

Sizes and Ordering Information

Placental tissue sourceProduct descriptionPart #
Lyopreserved umbilical tissueSTRAVIX PL 2 x 2 cm (4 cm2)PS61022
STRAVIX PL 2 x 4 cm (8 cm2)PS61024
STRAVIX PL 3 x 6 cm (18 cm2)PS61036
Cryopreserved Umbilical TissueSTRAVIX 2 x 2 cm (4 cm2)PS60006
STRAVIX 2 x 4 cm (8 cm2)PS60005
STRAVIX 3 x 6 cm (18 cm2)PS60008
STRAVIX Meshed 3 x 6 cm (18 cm2*)PS60036
   
*PS60036 can be stretched to cover up to 30 cm2 

Customer Information

Please see each products’ Instructions for Use for important safety information including approved uses.

STRAVIX PL & STRAVIX Customer Care:

  • T: 888-674-9551
  • F 443-283-4419

Osiris, STRAVIX PL and STRAVIX Tissue are trademarks of Osiris Therapeutics, Inc., a wholly owned direct subsidiary of Smith+Nephew Consolidated, Inc.
All Trademarks acknowledged.


Recall and Complaints

Customer will provide such support and assistance as S+N may reasonably request in the event of a general or limited voluntary or mandatory recall of the Product(s). Customer shall promptly report any complaint in respect of the Products to complaints@smith-nephew.com.

Terms & Conditions and Warranties

 

Citations

1. Dhall S, et al. Bioact Mater. 2018; 4(1): 97-106.

2. Data on file at Osiris Therapeutics, Inc

3. Woo KY. Woundsource (White Paper) 2014.

Title

Text